亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China

医学 耐火材料(行星科学) 成本效益分析 成本效益 淋巴瘤 肿瘤科 中国 支付意愿 内科学 天体生物学 风险分析(工程) 物理 经济 微观经济学 法学 政治学
作者
Ziyi Lin,Chenyu Zuo,Yifan Jiang,Wen Su,Xing Yao,Man Yu,Qiong Wu,Jianwei Xuan
出处
期刊:Value in health regional issues [Elsevier BV]
卷期号:37: 41-48 被引量:6
标识
DOI:10.1016/j.vhri.2023.03.006
摘要

Objectives Relmacabtagene autoleucel (relma-cel) was recently approved in China for treating relapsed or refractory large B-cell lymphoma (r/r LBCL). We conducted a cost-effectiveness analysis from the perspective of Chinese healthcare system. Methods A mixture-cure model was developed to project life-years (LYs), quality-adjusted LYs (QALYs), and overall direct cost with a lifetime horizon for patients with r/r LBCL treated with relma-cel versus salvage chemotherapy. Patient-level data from RELIANCE trial and published data from Collaborative Trial in Relapsed Aggressive Lymphoma extension study were used to inform the model. The incremental cost-effectiveness ratio (ICER) was estimated and cost-effectiveness was evaluated at the willingness-to-pay threshold of 3 times the national gross domestic product per capita. Results The model projected that treatment with relma-cel was associated with incremental gains of 5.11 LYs and 5.26 QALYs compared with salvage chemotherapy at an increased cost of ¥1 067 430 (∼$154 152), resulting in an ICER of ¥203 137 (∼$29 435) per QALY. The model was most sensitive to the uncertainty around the estimated cure rate. The ICER of relma-cel was within the willingness-to-pay threshold in the base case and the probability of relma-cel treatment being considered cost-effective was approximately 74%. Conclusions Compared with salvage chemotherapy, treatment with relma-cel for r/r LBCL in patients who have failed at least 2 lines of systemic therapy is within the cost-effective range from the perspective of Chinese healthcare system and represents a good use of healthcare resources.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
椰子云发布了新的文献求助10
2秒前
学术雷锋发布了新的文献求助10
5秒前
Moon完成签到 ,获得积分10
9秒前
天真的乐驹完成签到 ,获得积分10
13秒前
李健的小迷弟的应助被郦稀采纳,获得10
13秒前
Moon关注了科研通微信公众号
13秒前
14秒前
乐康完成签到,获得积分10
14秒前
17秒前
复杂惜珊完成签到,获得积分10
24秒前
cx完成签到,获得积分10
29秒前
机灵伟诚完成签到,获得积分10
29秒前
学霸业的应助被纯情的阁采纳,获得10
31秒前
极限001的应助被纯情的阁采纳,获得50
31秒前
Maestro_S的应助被纯情的阁采纳,获得10
31秒前
Nikkie2411的应助被纯情的阁采纳,获得10
31秒前
34秒前
35秒前
369ninja的应助被科研通管家采纳,获得10
37秒前
丘比特的应助被科研通管家采纳,获得10
37秒前
手打鱼丸完成签到 ,获得积分10
37秒前
37秒前
完美世界的应助被科研通管家采纳,获得10
37秒前
莫名乐乐完成签到,获得积分10
37秒前
FashionBoy的应助被科研通管家采纳,获得10
37秒前
SciGPT的应助被科研通管家采纳,获得10
37秒前
Akim的应助被纯情的阁采纳,获得10
37秒前
null的应助被科研通管家采纳,获得10
37秒前
38秒前
隐形曼青的应助被纯情的阁采纳,获得10
38秒前
null的应助被科研通管家采纳,获得10
38秒前
wanci的应助被科研通管家采纳,获得30
38秒前
大个的应助被纯情的阁采纳,获得30
38秒前
38秒前
学霸业的应助被纯情的阁采纳,获得10
38秒前
null的应助被科研通管家采纳,获得10
38秒前
祟祟发布了新的文献求助20
38秒前
研友_VZG7GZ的应助被纯情的阁采纳,获得30
38秒前
极限001的应助被纯情的阁采纳,获得50
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277